BioSpace News Archive

Cholinesterase inhibitors, also known as acetylcholine inhibitors, are a group of drugs that are used to prevent the routine breakdown of acetylcholine in the body

Analyses of pivotal study data of Dysport® reveal a large proportion of study patients did not require retreatment for at least 12 weeks

Ashion Analytics LLC, a CLIA-certified and CAP-accredited clinical laboratory announced that they will present data at the 2021 American Society for Clinical Oncology Gastrointestinal virtual meeting.

Lexaria Bioscience Corp. (NASDAQ:LEXX)(NASDAQ:LEXXW)(CSE:LXX)) today announced the closing of its previously announced underwritten public offering (the of 1,828,571 units, each unit consisting of one share of common stock and one warrant to purchase one share of common stock at a public offering price of $5.25 per unit (all prices in US$).

Fund will provide support for minority-owned early-stage healthcare companies and is a component of Lilly’s racial justice efforts

All three efficacy endpoints (PFS, OS and ORR) in the FIGHT Phase 2 trial met pre-specified statistical significance 2021 priorities for the bemarituzumab program include collaborating with regulatory agencies on next steps, initiating a global Phase 3 trial in gastric and GEJ cancers and evaluating bemarituzumab in other epithelial cancers that overexpress FGFR2b

Nuance Communications, Inc. (NASDAQ: NUAN) today announced that it will release its first quarter fiscal 2021 results on Monday, February 8, 2021 after the market close.

- Average Daily Testing in January 2021 to Date Up 158% Over December 2020, Driven Primarily by Scale Up in Testing Contracts - - Company Increases Production of Assay Kits (Tests) and Sample Collection Kits to Meet Further Demand -

Tris Pharma, Inc. announced that it will present pivotal efficacy and safety data on its new amphetamine extended-release tablet at the virtual annual meeting of American Professional Society of ADHD and Related Disorders to be held from Friday, January 15 through Sunday, January 17, 2021.

Catalyst Biosciences, Inc. (NASDAQ: CBIO) today announced that the members of its management team will participate in a fireside chat hosted by LifeSci Capital on Tuesday, January 19, 2021 at 1:00 pm Eastern Time.